Annexon biosciences announces clinical and preclinical data highlighting potential of complement-targeting programs at the 63rd ash annual meeting & exposition

Brisbane, calif., dec. 13, 2021 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced safety and dose-response data from its phase 1 clinical trial of anx009, the company's subcutaneously administered product candidate that is designed to block the activity of c1q and the entire classical complement pathway. in addition, annexon reported preclinical data supporting the role of the complement pathway in warm autoimmune hemolytic anemia (waiha). the data were presented during two poster sessions at the 63rd american society of hematology (ash) annual meeting & exposition.
ANNX Ratings Summary
ANNX Quant Ranking